Mirati Therapeutics Inc $ 77.02 1.07 (1.41%)
Volume:
533,212
Avg Vol (1m):
557,548
Market Cap $:
3.03 Bil
Enterprise Value $:
2.54 Bil
P/E (TTM):
0.00
P/B:
5.89
| Earnings Power Value | ||
| Net Current Asset Value | ||
| Tangible Book | ||
| Projected FCF | ||
| Median P/S Value | ||
|
Price: $77.02 | ||
Manual of Stocks™ Web
Financial Strength | 10/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | No Debt | ||
| Equity-to-Asset | 0.94 | ||
| Interest Coverage | No Debt | ||
| Piotroski F-Score | 4 | ||
| Altman Z-Score | 60.53 | ||
| Beneish M-Score | -2.99 | ||
| WACC vs ROIC | |||
Profitability | 2/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -2822.16 | ||
| Net Margin % | -2692.01 | ||
| ROE % | -49.73 | ||
| ROA % | -45.79 | ||
| ROC (Joel Greenblatt) % | -33575.94 | ||
| 3-Year EBITDA Growth Rate | 4.6 | ||
| 3-Year EPS without NRI Growth Rate | 5.9 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 5.89 | ||
| PS Ratio | 487.47 | ||
| EV-to-EBIT | -17.06 | ||
| EV-to-EBITDA | -17.08 | ||
| EV-to-Revenue | 481.27 | ||
| Current Ratio | 17.57 | ||
| Quick Ratio | 17.57 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -25.4 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 5.9 | ||
| Price-to-Median-PS-Value | 3.76 | ||
| Earnings Yield (Greenblatt) % | -5.84 |